MKI67 and acute myeloid leukemia: We therefore immunostained for Ki-67, which revealed that AML cells taken from patients on Day 5 of PF-913 treatment stained more strongly than control cells; however, the proportion of stained cells decreased in samples taken at Weeks 2 and 4 as shown in Figure S2.